BRD2 and lymphoma: It also downregulated BRD2, BRD4, and MYC in vitro.713 In lymphoma, OTX015 stimulated the apoptosis of DLBCL cells with mutations in MYD88, CD79B, or CARD11, and repressed MYC- and E2F1-related expression.714 OTX015 showed mild efficacy in acute leukemia and lymphoma patients, while no efficacy was found in MM patients.715 CPI-0610, GSK525762, RO6870810, and FT-1101 are being explored in hematologic malignancies in clinical trials.716 Apart from the classic BET inhibitors, BET-targeted PROTACs have been reported.